Algernon Pharmaceuticals’ subsidiary, Algernon NeuroScience, has appointed Dr. Sándor Nardai as the Principal Investigator for its Phase 2a DMT stroke study. Dr. Nardai, a leading European stroke expert, headed the pre-clinical rat study that showed significant motor function recovery and reduced infarct volumes in subjects treated with DMT. The Phase 2a study, a randomized, double-blind, placebo-controlled trial involving 40 stroke patients, is slated to commence patient enrollment in Q3 2025.
This upcoming clinical trial holds substantial implications for the stroke treatment landscape. Dr. Nardai’s prior research provides compelling pre-clinical evidence for DMT’s potential neuroprotective properties. Positive results from the Phase 2a trial could validate these findings in humans, potentially leading to a novel therapeutic approach for stroke, a condition with limited treatment options. The study’s focus on safety, lesion volume, biomarkers, motor and cognitive function, depression, and mortality offers a comprehensive assessment of DMT’s potential benefits for stroke patients.
The Phase 2a trial will evaluate the safety and efficacy of DMT in 40 stroke patients. It builds upon promising pre-clinical data demonstrating DMT’s ability to promote neuroprotection and functional recovery. Algernon has strategically positioned itself with patent filings for DMT pamoate and nicotinate, along with claims for its use in stroke and TBI, including combination therapy with stroke rehabilitation.
A successful Phase 2a trial could significantly advance DMT as a potential stroke treatment. This would not only validate Algernon’s research and development efforts but could also pave the way for larger clinical trials and eventual regulatory approval. Positive results could transform the treatment paradigm for stroke, offering hope for improved patient outcomes.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
1 Comment
DMT: The “Spirit Molecule” Showing Real Promise in Brain Repair – Cosmic Curiosityy
1 month ago[…] A Phase 2a clinical trial — enrolling 40 ischemic stroke patients — is scheduled to begin in Q3 2025 in Hungary, led by principal investigator Dr. Sándor Nardai. This randomized, double-blind, placebo-controlled study will test whether DMT can meaningfully improve recovery outcomes.(Clinical Trial Vanguard, 2025) […]